nodes	percent_of_prediction	percent_of_DWPC	metapath
Nedocromil—HSP90AA1—oviduct—ovarian cancer	0.0395	0.139	CbGeAlD
Nedocromil—CYSLTR2—female reproductive system—ovarian cancer	0.0226	0.0795	CbGeAlD
Nedocromil—FPR1—bone marrow—ovarian cancer	0.0192	0.0676	CbGeAlD
Nedocromil—PTGDR—bone marrow—ovarian cancer	0.0181	0.0638	CbGeAlD
Nedocromil—PTGDR—vagina—ovarian cancer	0.0174	0.0611	CbGeAlD
Nedocromil—Sensation of warmth—Melphalan—ovarian cancer	0.0148	0.053	CcSEcCtD
Nedocromil—HSP90AA1—myometrium—ovarian cancer	0.0127	0.0445	CbGeAlD
Nedocromil—HSP90AA1—embryo—ovarian cancer	0.0122	0.0428	CbGeAlD
Nedocromil—PTGDR—lymph node—ovarian cancer	0.0112	0.0395	CbGeAlD
Nedocromil—HSP90AA1—epithelium—ovarian cancer	0.00993	0.035	CbGeAlD
Nedocromil—HSP90AA1—uterine cervix—ovarian cancer	0.00985	0.0347	CbGeAlD
Nedocromil—CYSLTR1—uterus—ovarian cancer	0.00946	0.0333	CbGeAlD
Nedocromil—HSP90AA1—decidua—ovarian cancer	0.00938	0.033	CbGeAlD
Nedocromil—HSP90AA1—endometrium—ovarian cancer	0.00891	0.0313	CbGeAlD
Nedocromil—CYSLTR1—female reproductive system—ovarian cancer	0.0085	0.0299	CbGeAlD
Nedocromil—HSP90AA1—gonad—ovarian cancer	0.00826	0.0291	CbGeAlD
Nedocromil—HSP90AA1—uterus—ovarian cancer	0.00821	0.0289	CbGeAlD
Nedocromil—CYSLTR1—bone marrow—ovarian cancer	0.00803	0.0283	CbGeAlD
Nedocromil—CYSLTR1—vagina—ovarian cancer	0.00769	0.0271	CbGeAlD
Nedocromil—HSP90AA1—female reproductive system—ovarian cancer	0.00738	0.026	CbGeAlD
Nedocromil—HSP90AA1—bone marrow—ovarian cancer	0.00697	0.0245	CbGeAlD
Nedocromil—HSP90AA1—female gonad—ovarian cancer	0.00671	0.0236	CbGeAlD
Nedocromil—HSP90AA1—vagina—ovarian cancer	0.00667	0.0235	CbGeAlD
Nedocromil—HSP90AA1—testis—ovarian cancer	0.00595	0.021	CbGeAlD
Nedocromil—Rash erythematous—Topotecan—ovarian cancer	0.00532	0.019	CcSEcCtD
Nedocromil—Feeling hot—Melphalan—ovarian cancer	0.00509	0.0182	CcSEcCtD
Nedocromil—Leukopenia—Altretamine—ovarian cancer	0.00504	0.018	CcSEcCtD
Nedocromil—CYSLTR1—lymph node—ovarian cancer	0.00497	0.0175	CbGeAlD
Nedocromil—Disorder sight—Paclitaxel—ovarian cancer	0.00493	0.0176	CcSEcCtD
Nedocromil—HSP90AA1—lymph node—ovarian cancer	0.00432	0.0152	CbGeAlD
Nedocromil—Fatigue—Altretamine—ovarian cancer	0.00396	0.0142	CcSEcCtD
Nedocromil—Ear pain—Topotecan—ovarian cancer	0.00347	0.0124	CcSEcCtD
Nedocromil—Asthenia—Altretamine—ovarian cancer	0.0033	0.0118	CcSEcCtD
Nedocromil—Rash erythematous—Paclitaxel—ovarian cancer	0.00306	0.011	CcSEcCtD
Nedocromil—Dizziness—Altretamine—ovarian cancer	0.00304	0.0109	CcSEcCtD
Nedocromil—Vomiting—Altretamine—ovarian cancer	0.00292	0.0105	CcSEcCtD
Nedocromil—Dysphonia—Paclitaxel—ovarian cancer	0.00285	0.0102	CcSEcCtD
Nedocromil—Nausea—Altretamine—ovarian cancer	0.00273	0.00977	CcSEcCtD
Nedocromil—Pain—Carboplatin—ovarian cancer	0.00272	0.00972	CcSEcCtD
Nedocromil—Viral infection—Paclitaxel—ovarian cancer	0.0026	0.00929	CcSEcCtD
Nedocromil—Rash erythematous—Docetaxel—ovarian cancer	0.0026	0.00929	CcSEcCtD
Nedocromil—Pneumonia—Chlorambucil—ovarian cancer	0.00258	0.00922	CcSEcCtD
Nedocromil—Otitis media—Docetaxel—ovarian cancer	0.00255	0.00914	CcSEcCtD
Nedocromil—Body temperature increased—Carboplatin—ovarian cancer	0.00251	0.00899	CcSEcCtD
Nedocromil—Pneumonia—Topotecan—ovarian cancer	0.00229	0.00821	CcSEcCtD
Nedocromil—Rhinitis—Topotecan—ovarian cancer	0.00205	0.00734	CcSEcCtD
Nedocromil—Pharyngitis—Topotecan—ovarian cancer	0.00203	0.00727	CcSEcCtD
Nedocromil—Ear pain—Paclitaxel—ovarian cancer	0.002	0.00714	CcSEcCtD
Nedocromil—Pneumonia—Vinorelbine—ovarian cancer	0.00196	0.00702	CcSEcCtD
Nedocromil—Tremor—Chlorambucil—ovarian cancer	0.00188	0.00671	CcSEcCtD
Nedocromil—Nasal congestion—Paclitaxel—ovarian cancer	0.00187	0.00669	CcSEcCtD
Nedocromil—Leukopenia—Chlorambucil—ovarian cancer	0.00179	0.00641	CcSEcCtD
Nedocromil—Rash erythematous—Epirubicin—ovarian cancer	0.00175	0.00627	CcSEcCtD
Nedocromil—Otitis media—Epirubicin—ovarian cancer	0.00172	0.00616	CcSEcCtD
Nedocromil—Feeling hot—Epirubicin—ovarian cancer	0.00171	0.00611	CcSEcCtD
Nedocromil—Stinging—Epirubicin—ovarian cancer	0.00166	0.00592	CcSEcCtD
Nedocromil—Dysphonia—Epirubicin—ovarian cancer	0.00163	0.00583	CcSEcCtD
Nedocromil—Rash erythematous—Doxorubicin—ovarian cancer	0.00162	0.0058	CcSEcCtD
Nedocromil—Leukopenia—Topotecan—ovarian cancer	0.0016	0.00571	CcSEcCtD
Nedocromil—Otitis media—Doxorubicin—ovarian cancer	0.00159	0.0057	CcSEcCtD
Nedocromil—Feeling hot—Doxorubicin—ovarian cancer	0.00158	0.00566	CcSEcCtD
Nedocromil—Leukopenia—Melphalan—ovarian cancer	0.00156	0.00559	CcSEcCtD
Nedocromil—Cough—Topotecan—ovarian cancer	0.00156	0.00556	CcSEcCtD
Nedocromil—Stinging—Doxorubicin—ovarian cancer	0.00153	0.00548	CcSEcCtD
Nedocromil—Cough—Melphalan—ovarian cancer	0.00152	0.00545	CcSEcCtD
Nedocromil—Chest pain—Topotecan—ovarian cancer	0.00152	0.00543	CcSEcCtD
Nedocromil—Dysphonia—Doxorubicin—ovarian cancer	0.00151	0.0054	CcSEcCtD
Nedocromil—Chest pain—Melphalan—ovarian cancer	0.00149	0.00532	CcSEcCtD
Nedocromil—Viral infection—Epirubicin—ovarian cancer	0.00149	0.00531	CcSEcCtD
Nedocromil—Influenza—Paclitaxel—ovarian cancer	0.00147	0.00527	CcSEcCtD
Nedocromil—Cough increased—Epirubicin—ovarian cancer	0.00147	0.00524	CcSEcCtD
Nedocromil—Anaphylactic shock—Topotecan—ovarian cancer	0.00145	0.0052	CcSEcCtD
Nedocromil—Dyspepsia—Chlorambucil—ovarian cancer	0.00144	0.00515	CcSEcCtD
Nedocromil—Anaphylactic shock—Melphalan—ovarian cancer	0.00142	0.0051	CcSEcCtD
Nedocromil—Bronchitis—Paclitaxel—ovarian cancer	0.00142	0.00506	CcSEcCtD
Nedocromil—Gastrointestinal disorder—Chlorambucil—ovarian cancer	0.00141	0.00505	CcSEcCtD
Nedocromil—Fatigue—Chlorambucil—ovarian cancer	0.00141	0.00504	CcSEcCtD
Nedocromil—Pain—Chlorambucil—ovarian cancer	0.0014	0.005	CcSEcCtD
Nedocromil—Viral infection—Doxorubicin—ovarian cancer	0.00137	0.00492	CcSEcCtD
Nedocromil—Upper respiratory tract infection—Paclitaxel—ovarian cancer	0.00137	0.00489	CcSEcCtD
Nedocromil—Leukopenia—Vinorelbine—ovarian cancer	0.00136	0.00488	CcSEcCtD
Nedocromil—Cough increased—Doxorubicin—ovarian cancer	0.00136	0.00485	CcSEcCtD
Nedocromil—Gastrointestinal pain—Chlorambucil—ovarian cancer	0.00134	0.00478	CcSEcCtD
Nedocromil—Cough—Vinorelbine—ovarian cancer	0.00133	0.00476	CcSEcCtD
Nedocromil—Pneumonia—Paclitaxel—ovarian cancer	0.00132	0.00472	CcSEcCtD
Nedocromil—Urticaria—Chlorambucil—ovarian cancer	0.0013	0.00464	CcSEcCtD
Nedocromil—Chest pain—Vinorelbine—ovarian cancer	0.0013	0.00464	CcSEcCtD
Nedocromil—Dyspnoea—Topotecan—ovarian cancer	0.0013	0.00464	CcSEcCtD
Nedocromil—Body temperature increased—Chlorambucil—ovarian cancer	0.00129	0.00462	CcSEcCtD
Nedocromil—Abdominal pain—Chlorambucil—ovarian cancer	0.00129	0.00462	CcSEcCtD
Nedocromil—Dyspepsia—Topotecan—ovarian cancer	0.00128	0.00458	CcSEcCtD
Nedocromil—Conjunctivitis—Paclitaxel—ovarian cancer	0.00128	0.00456	CcSEcCtD
Nedocromil—Dyspnoea—Melphalan—ovarian cancer	0.00127	0.00454	CcSEcCtD
Nedocromil—Gastrointestinal disorder—Topotecan—ovarian cancer	0.00126	0.00449	CcSEcCtD
Nedocromil—Fatigue—Topotecan—ovarian cancer	0.00125	0.00449	CcSEcCtD
Nedocromil—Dyspepsia—Melphalan—ovarian cancer	0.00125	0.00449	CcSEcCtD
Nedocromil—Anaphylactic shock—Vinorelbine—ovarian cancer	0.00124	0.00445	CcSEcCtD
Nedocromil—Pain—Topotecan—ovarian cancer	0.00124	0.00445	CcSEcCtD
Nedocromil—Sinusitis—Paclitaxel—ovarian cancer	0.00123	0.00441	CcSEcCtD
Nedocromil—Gastrointestinal disorder—Melphalan—ovarian cancer	0.00123	0.0044	CcSEcCtD
Nedocromil—Fatigue—Melphalan—ovarian cancer	0.00123	0.00439	CcSEcCtD
Nedocromil—Pain—Melphalan—ovarian cancer	0.00122	0.00436	CcSEcCtD
Nedocromil—Hypersensitivity—Chlorambucil—ovarian cancer	0.0012	0.00431	CcSEcCtD
Nedocromil—Gastrointestinal pain—Topotecan—ovarian cancer	0.00119	0.00426	CcSEcCtD
Nedocromil—Rhinitis—Paclitaxel—ovarian cancer	0.00118	0.00423	CcSEcCtD
Nedocromil—Asthenia—Chlorambucil—ovarian cancer	0.00117	0.00419	CcSEcCtD
Nedocromil—Pharyngitis—Paclitaxel—ovarian cancer	0.00117	0.00418	CcSEcCtD
Nedocromil—Urticaria—Topotecan—ovarian cancer	0.00116	0.00413	CcSEcCtD
Nedocromil—Abdominal pain—Topotecan—ovarian cancer	0.00115	0.00411	CcSEcCtD
Nedocromil—Body temperature increased—Topotecan—ovarian cancer	0.00115	0.00411	CcSEcCtD
Nedocromil—Visual impairment—Paclitaxel—ovarian cancer	0.00114	0.00406	CcSEcCtD
Nedocromil—Urticaria—Melphalan—ovarian cancer	0.00113	0.00405	CcSEcCtD
Nedocromil—Pneumonia—Docetaxel—ovarian cancer	0.00112	0.004	CcSEcCtD
Nedocromil—Diarrhoea—Chlorambucil—ovarian cancer	0.00112	0.004	CcSEcCtD
Nedocromil—Dyspnoea—Vinorelbine—ovarian cancer	0.00111	0.00397	CcSEcCtD
Nedocromil—Eczema—Epirubicin—ovarian cancer	0.00108	0.00388	CcSEcCtD
Nedocromil—Conjunctivitis—Docetaxel—ovarian cancer	0.00108	0.00387	CcSEcCtD
Nedocromil—Gastrointestinal disorder—Vinorelbine—ovarian cancer	0.00107	0.00384	CcSEcCtD
Nedocromil—Fatigue—Vinorelbine—ovarian cancer	0.00107	0.00384	CcSEcCtD
Nedocromil—Hypersensitivity—Topotecan—ovarian cancer	0.00107	0.00383	CcSEcCtD
Nedocromil—Pain—Vinorelbine—ovarian cancer	0.00106	0.00381	CcSEcCtD
Nedocromil—Hypersensitivity—Melphalan—ovarian cancer	0.00105	0.00375	CcSEcCtD
Nedocromil—Asthenia—Topotecan—ovarian cancer	0.00104	0.00373	CcSEcCtD
Nedocromil—Vomiting—Chlorambucil—ovarian cancer	0.00104	0.00372	CcSEcCtD
Nedocromil—Asthenia—Melphalan—ovarian cancer	0.00102	0.00366	CcSEcCtD
Nedocromil—Gastrointestinal pain—Vinorelbine—ovarian cancer	0.00102	0.00364	CcSEcCtD
Nedocromil—Dysgeusia—Paclitaxel—ovarian cancer	0.001	0.00359	CcSEcCtD
Nedocromil—Eczema—Doxorubicin—ovarian cancer	0.001	0.00359	CcSEcCtD
Nedocromil—Rhinitis—Docetaxel—ovarian cancer	0.001	0.00358	CcSEcCtD
Nedocromil—Diarrhoea—Topotecan—ovarian cancer	0.000995	0.00356	CcSEcCtD
Nedocromil—Pharyngitis—Docetaxel—ovarian cancer	0.000991	0.00355	CcSEcCtD
Nedocromil—Urticaria—Vinorelbine—ovarian cancer	0.000989	0.00354	CcSEcCtD
Nedocromil—Abdominal pain—Vinorelbine—ovarian cancer	0.000984	0.00352	CcSEcCtD
Nedocromil—Body temperature increased—Vinorelbine—ovarian cancer	0.000984	0.00352	CcSEcCtD
Nedocromil—Diarrhoea—Melphalan—ovarian cancer	0.000975	0.00349	CcSEcCtD
Nedocromil—Nausea—Chlorambucil—ovarian cancer	0.000971	0.00347	CcSEcCtD
Nedocromil—Visual impairment—Docetaxel—ovarian cancer	0.000962	0.00344	CcSEcCtD
Nedocromil—Dizziness—Topotecan—ovarian cancer	0.000962	0.00344	CcSEcCtD
Nedocromil—Tremor—Paclitaxel—ovarian cancer	0.000961	0.00344	CcSEcCtD
Nedocromil—Vomiting—Topotecan—ovarian cancer	0.000925	0.00331	CcSEcCtD
Nedocromil—Leukopenia—Paclitaxel—ovarian cancer	0.000918	0.00328	CcSEcCtD
Nedocromil—Rash—Topotecan—ovarian cancer	0.000917	0.00328	CcSEcCtD
Nedocromil—Hypersensitivity—Vinorelbine—ovarian cancer	0.000917	0.00328	CcSEcCtD
Nedocromil—Dermatitis—Topotecan—ovarian cancer	0.000916	0.00328	CcSEcCtD
Nedocromil—Headache—Topotecan—ovarian cancer	0.000911	0.00326	CcSEcCtD
Nedocromil—Vomiting—Melphalan—ovarian cancer	0.000906	0.00324	CcSEcCtD
Nedocromil—Rash—Melphalan—ovarian cancer	0.000898	0.00321	CcSEcCtD
Nedocromil—Dermatitis—Melphalan—ovarian cancer	0.000897	0.00321	CcSEcCtD
Nedocromil—Cough—Paclitaxel—ovarian cancer	0.000895	0.0032	CcSEcCtD
Nedocromil—Asthenia—Vinorelbine—ovarian cancer	0.000893	0.00319	CcSEcCtD
Nedocromil—Chest pain—Paclitaxel—ovarian cancer	0.000873	0.00312	CcSEcCtD
Nedocromil—Nausea—Topotecan—ovarian cancer	0.000864	0.00309	CcSEcCtD
Nedocromil—Dry mouth—Paclitaxel—ovarian cancer	0.000854	0.00306	CcSEcCtD
Nedocromil—Diarrhoea—Vinorelbine—ovarian cancer	0.000852	0.00305	CcSEcCtD
Nedocromil—Dysgeusia—Docetaxel—ovarian cancer	0.000851	0.00305	CcSEcCtD
Nedocromil—Nausea—Melphalan—ovarian cancer	0.000846	0.00303	CcSEcCtD
Nedocromil—Influenza—Epirubicin—ovarian cancer	0.000842	0.00301	CcSEcCtD
Nedocromil—Anaphylactic shock—Paclitaxel—ovarian cancer	0.000837	0.00299	CcSEcCtD
Nedocromil—Eosinophilia—Epirubicin—ovarian cancer	0.000833	0.00298	CcSEcCtD
Nedocromil—Dizziness—Vinorelbine—ovarian cancer	0.000823	0.00294	CcSEcCtD
Nedocromil—Bronchitis—Epirubicin—ovarian cancer	0.000809	0.0029	CcSEcCtD
Nedocromil—Vomiting—Vinorelbine—ovarian cancer	0.000791	0.00283	CcSEcCtD
Nedocromil—Rash—Vinorelbine—ovarian cancer	0.000785	0.00281	CcSEcCtD
Nedocromil—Dermatitis—Vinorelbine—ovarian cancer	0.000784	0.0028	CcSEcCtD
Nedocromil—Upper respiratory tract infection—Epirubicin—ovarian cancer	0.000782	0.0028	CcSEcCtD
Nedocromil—Headache—Vinorelbine—ovarian cancer	0.00078	0.00279	CcSEcCtD
Nedocromil—Influenza—Doxorubicin—ovarian cancer	0.000779	0.00279	CcSEcCtD
Nedocromil—Leukopenia—Docetaxel—ovarian cancer	0.000778	0.00278	CcSEcCtD
Nedocromil—Eosinophilia—Doxorubicin—ovarian cancer	0.000771	0.00276	CcSEcCtD
Nedocromil—Cough—Docetaxel—ovarian cancer	0.000759	0.00271	CcSEcCtD
Nedocromil—Pneumonia—Epirubicin—ovarian cancer	0.000755	0.0027	CcSEcCtD
Nedocromil—Bronchitis—Doxorubicin—ovarian cancer	0.000749	0.00268	CcSEcCtD
Nedocromil—Dyspnoea—Paclitaxel—ovarian cancer	0.000746	0.00267	CcSEcCtD
Nedocromil—Chest pain—Docetaxel—ovarian cancer	0.00074	0.00265	CcSEcCtD
Nedocromil—Nausea—Vinorelbine—ovarian cancer	0.000739	0.00264	CcSEcCtD
Nedocromil—Dyspepsia—Paclitaxel—ovarian cancer	0.000737	0.00264	CcSEcCtD
Nedocromil—Conjunctivitis—Epirubicin—ovarian cancer	0.000729	0.00261	CcSEcCtD
Nedocromil—Dry mouth—Docetaxel—ovarian cancer	0.000724	0.00259	CcSEcCtD
Nedocromil—Upper respiratory tract infection—Doxorubicin—ovarian cancer	0.000724	0.00259	CcSEcCtD
Nedocromil—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.000723	0.00259	CcSEcCtD
Nedocromil—Fatigue—Paclitaxel—ovarian cancer	0.000722	0.00258	CcSEcCtD
Nedocromil—Pain—Paclitaxel—ovarian cancer	0.000716	0.00256	CcSEcCtD
Nedocromil—Anaphylactic shock—Docetaxel—ovarian cancer	0.00071	0.00254	CcSEcCtD
Nedocromil—Sinusitis—Epirubicin—ovarian cancer	0.000704	0.00252	CcSEcCtD
Nedocromil—Pneumonia—Doxorubicin—ovarian cancer	0.000698	0.0025	CcSEcCtD
Nedocromil—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.000684	0.00245	CcSEcCtD
Nedocromil—Rhinitis—Epirubicin—ovarian cancer	0.000675	0.00242	CcSEcCtD
Nedocromil—Conjunctivitis—Doxorubicin—ovarian cancer	0.000675	0.00241	CcSEcCtD
Nedocromil—Pharyngitis—Epirubicin—ovarian cancer	0.000669	0.00239	CcSEcCtD
Nedocromil—Urticaria—Paclitaxel—ovarian cancer	0.000665	0.00238	CcSEcCtD
Nedocromil—Abdominal pain—Paclitaxel—ovarian cancer	0.000662	0.00237	CcSEcCtD
Nedocromil—Body temperature increased—Paclitaxel—ovarian cancer	0.000662	0.00237	CcSEcCtD
Nedocromil—Sinusitis—Doxorubicin—ovarian cancer	0.000651	0.00233	CcSEcCtD
Nedocromil—Visual impairment—Epirubicin—ovarian cancer	0.000649	0.00232	CcSEcCtD
Nedocromil—Dyspnoea—Docetaxel—ovarian cancer	0.000633	0.00226	CcSEcCtD
Nedocromil—Rhinitis—Doxorubicin—ovarian cancer	0.000625	0.00224	CcSEcCtD
Nedocromil—Dyspepsia—Docetaxel—ovarian cancer	0.000625	0.00223	CcSEcCtD
Nedocromil—Pharyngitis—Doxorubicin—ovarian cancer	0.000619	0.00221	CcSEcCtD
Nedocromil—Hypersensitivity—Paclitaxel—ovarian cancer	0.000617	0.00221	CcSEcCtD
Nedocromil—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.000613	0.00219	CcSEcCtD
Nedocromil—Fatigue—Docetaxel—ovarian cancer	0.000612	0.00219	CcSEcCtD
Nedocromil—Pain—Docetaxel—ovarian cancer	0.000607	0.00217	CcSEcCtD
Nedocromil—Visual impairment—Doxorubicin—ovarian cancer	0.000601	0.00215	CcSEcCtD
Nedocromil—Asthenia—Paclitaxel—ovarian cancer	0.000601	0.00215	CcSEcCtD
Nedocromil—Gastrointestinal pain—Docetaxel—ovarian cancer	0.00058	0.00208	CcSEcCtD
Nedocromil—Dysgeusia—Epirubicin—ovarian cancer	0.000574	0.00205	CcSEcCtD
Nedocromil—Diarrhoea—Paclitaxel—ovarian cancer	0.000573	0.00205	CcSEcCtD
Nedocromil—Body temperature increased—Docetaxel—ovarian cancer	0.000561	0.00201	CcSEcCtD
Nedocromil—Abdominal pain—Docetaxel—ovarian cancer	0.000561	0.00201	CcSEcCtD
Nedocromil—Dizziness—Paclitaxel—ovarian cancer	0.000554	0.00198	CcSEcCtD
Nedocromil—Vomiting—Paclitaxel—ovarian cancer	0.000532	0.0019	CcSEcCtD
Nedocromil—Dysgeusia—Doxorubicin—ovarian cancer	0.000531	0.0019	CcSEcCtD
Nedocromil—Rash—Paclitaxel—ovarian cancer	0.000528	0.00189	CcSEcCtD
Nedocromil—Dermatitis—Paclitaxel—ovarian cancer	0.000527	0.00189	CcSEcCtD
Nedocromil—Leukopenia—Epirubicin—ovarian cancer	0.000525	0.00188	CcSEcCtD
Nedocromil—Headache—Paclitaxel—ovarian cancer	0.000524	0.00188	CcSEcCtD
Nedocromil—Hypersensitivity—Docetaxel—ovarian cancer	0.000523	0.00187	CcSEcCtD
Nedocromil—Cough—Epirubicin—ovarian cancer	0.000512	0.00183	CcSEcCtD
Nedocromil—Asthenia—Docetaxel—ovarian cancer	0.000509	0.00182	CcSEcCtD
Nedocromil—Chest pain—Epirubicin—ovarian cancer	0.000499	0.00179	CcSEcCtD
Nedocromil—Nausea—Paclitaxel—ovarian cancer	0.000497	0.00178	CcSEcCtD
Nedocromil—Dry mouth—Epirubicin—ovarian cancer	0.000488	0.00175	CcSEcCtD
Nedocromil—Leukopenia—Doxorubicin—ovarian cancer	0.000486	0.00174	CcSEcCtD
Nedocromil—Diarrhoea—Docetaxel—ovarian cancer	0.000485	0.00174	CcSEcCtD
Nedocromil—Anaphylactic shock—Epirubicin—ovarian cancer	0.000479	0.00171	CcSEcCtD
Nedocromil—Cough—Doxorubicin—ovarian cancer	0.000473	0.00169	CcSEcCtD
Nedocromil—Dizziness—Docetaxel—ovarian cancer	0.000469	0.00168	CcSEcCtD
Nedocromil—Chest pain—Doxorubicin—ovarian cancer	0.000462	0.00165	CcSEcCtD
Nedocromil—Dry mouth—Doxorubicin—ovarian cancer	0.000452	0.00162	CcSEcCtD
Nedocromil—Vomiting—Docetaxel—ovarian cancer	0.000451	0.00161	CcSEcCtD
Nedocromil—Rash—Docetaxel—ovarian cancer	0.000447	0.0016	CcSEcCtD
Nedocromil—Dermatitis—Docetaxel—ovarian cancer	0.000447	0.0016	CcSEcCtD
Nedocromil—Headache—Docetaxel—ovarian cancer	0.000444	0.00159	CcSEcCtD
Nedocromil—Anaphylactic shock—Doxorubicin—ovarian cancer	0.000443	0.00158	CcSEcCtD
Nedocromil—Dyspnoea—Epirubicin—ovarian cancer	0.000427	0.00153	CcSEcCtD
Nedocromil—Nausea—Docetaxel—ovarian cancer	0.000421	0.00151	CcSEcCtD
Nedocromil—Dyspepsia—Epirubicin—ovarian cancer	0.000421	0.00151	CcSEcCtD
Nedocromil—Gastrointestinal disorder—Epirubicin—ovarian cancer	0.000413	0.00148	CcSEcCtD
Nedocromil—Fatigue—Epirubicin—ovarian cancer	0.000413	0.00148	CcSEcCtD
Nedocromil—Pain—Epirubicin—ovarian cancer	0.000409	0.00146	CcSEcCtD
Nedocromil—Dyspnoea—Doxorubicin—ovarian cancer	0.000395	0.00141	CcSEcCtD
Nedocromil—Gastrointestinal pain—Epirubicin—ovarian cancer	0.000391	0.0014	CcSEcCtD
Nedocromil—Dyspepsia—Doxorubicin—ovarian cancer	0.00039	0.00139	CcSEcCtD
Nedocromil—Gastrointestinal disorder—Doxorubicin—ovarian cancer	0.000382	0.00137	CcSEcCtD
Nedocromil—Fatigue—Doxorubicin—ovarian cancer	0.000382	0.00137	CcSEcCtD
Nedocromil—Urticaria—Epirubicin—ovarian cancer	0.00038	0.00136	CcSEcCtD
Nedocromil—Pain—Doxorubicin—ovarian cancer	0.000379	0.00135	CcSEcCtD
Nedocromil—Body temperature increased—Epirubicin—ovarian cancer	0.000378	0.00135	CcSEcCtD
Nedocromil—Abdominal pain—Epirubicin—ovarian cancer	0.000378	0.00135	CcSEcCtD
Nedocromil—Gastrointestinal pain—Doxorubicin—ovarian cancer	0.000362	0.0013	CcSEcCtD
Nedocromil—Hypersensitivity—Epirubicin—ovarian cancer	0.000353	0.00126	CcSEcCtD
Nedocromil—Urticaria—Doxorubicin—ovarian cancer	0.000352	0.00126	CcSEcCtD
Nedocromil—Abdominal pain—Doxorubicin—ovarian cancer	0.00035	0.00125	CcSEcCtD
Nedocromil—Body temperature increased—Doxorubicin—ovarian cancer	0.00035	0.00125	CcSEcCtD
Nedocromil—Asthenia—Epirubicin—ovarian cancer	0.000343	0.00123	CcSEcCtD
Nedocromil—Diarrhoea—Epirubicin—ovarian cancer	0.000327	0.00117	CcSEcCtD
Nedocromil—Hypersensitivity—Doxorubicin—ovarian cancer	0.000326	0.00117	CcSEcCtD
Nedocromil—Asthenia—Doxorubicin—ovarian cancer	0.000318	0.00114	CcSEcCtD
Nedocromil—Dizziness—Epirubicin—ovarian cancer	0.000316	0.00113	CcSEcCtD
Nedocromil—Vomiting—Epirubicin—ovarian cancer	0.000304	0.00109	CcSEcCtD
Nedocromil—Diarrhoea—Doxorubicin—ovarian cancer	0.000303	0.00108	CcSEcCtD
Nedocromil—Rash—Epirubicin—ovarian cancer	0.000302	0.00108	CcSEcCtD
Nedocromil—Dermatitis—Epirubicin—ovarian cancer	0.000301	0.00108	CcSEcCtD
Nedocromil—Headache—Epirubicin—ovarian cancer	0.0003	0.00107	CcSEcCtD
Nedocromil—Dizziness—Doxorubicin—ovarian cancer	0.000293	0.00105	CcSEcCtD
Nedocromil—Nausea—Epirubicin—ovarian cancer	0.000284	0.00102	CcSEcCtD
Nedocromil—Vomiting—Doxorubicin—ovarian cancer	0.000282	0.00101	CcSEcCtD
Nedocromil—Rash—Doxorubicin—ovarian cancer	0.000279	0.000999	CcSEcCtD
Nedocromil—Dermatitis—Doxorubicin—ovarian cancer	0.000279	0.000998	CcSEcCtD
Nedocromil—Headache—Doxorubicin—ovarian cancer	0.000277	0.000992	CcSEcCtD
Nedocromil—Nausea—Doxorubicin—ovarian cancer	0.000263	0.000941	CcSEcCtD
Nedocromil—FPR1—Signaling Pathways—CXCL8—ovarian cancer	0.000148	0.00034	CbGpPWpGaD
Nedocromil—FPR1—Signaling by GPCR—HRAS—ovarian cancer	0.000147	0.000337	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling by GPCR—MAPK3—ovarian cancer	0.000146	0.000335	CbGpPWpGaD
Nedocromil—CYSLTR1—GPCR downstream signaling—CXCL8—ovarian cancer	0.000145	0.000332	CbGpPWpGaD
Nedocromil—HSP90AA1—Cell Cycle—CCND1—ovarian cancer	0.000145	0.000332	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—CDKN1B—ovarian cancer	0.000145	0.000332	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—CDKN1B—ovarian cancer	0.000145	0.000332	CbGpPWpGaD
Nedocromil—FPR1—GPCR downstream signaling—AKT1—ovarian cancer	0.000143	0.000328	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—CXCL8—ovarian cancer	0.000143	0.000328	CbGpPWpGaD
Nedocromil—PTGDR—Signaling by GPCR—HRAS—ovarian cancer	0.000142	0.000326	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—CASP3—ovarian cancer	0.000142	0.000325	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—IL2—ovarian cancer	0.000142	0.000324	CbGpPWpGaD
Nedocromil—FPR1—Signaling by GPCR—IL6—ovarian cancer	0.000141	0.000323	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—PARP1—ovarian cancer	0.00014	0.00032	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—CDKN1B—ovarian cancer	0.00014	0.00032	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling by GPCR—MAPK1—ovarian cancer	0.000139	0.000318	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling by GPCR—EGFR—ovarian cancer	0.000139	0.000318	CbGpPWpGaD
Nedocromil—CYSLTR1—GPCR downstream signaling—IL2—ovarian cancer	0.000139	0.000318	CbGpPWpGaD
Nedocromil—PTGDR—GPCR downstream signaling—AKT1—ovarian cancer	0.000138	0.000317	CbGpPWpGaD
Nedocromil—HSP90AA1—Axon guidance—HRAS—ovarian cancer	0.000138	0.000317	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—CCND1—ovarian cancer	0.000138	0.000316	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—PIK3CB—ovarian cancer	0.000137	0.000314	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—CASP3—ovarian cancer	0.000137	0.000314	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—CTNNB1—ovarian cancer	0.000137	0.000314	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—IL2—ovarian cancer	0.000137	0.000313	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—CTNNB1—ovarian cancer	0.000137	0.000313	CbGpPWpGaD
Nedocromil—HSP90AA1—Developmental Biology—VEGFA—ovarian cancer	0.000136	0.000313	CbGpPWpGaD
Nedocromil—PTGDR—Signaling by GPCR—IL6—ovarian cancer	0.000136	0.000312	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—PPP2R1A—ovarian cancer	0.000136	0.000311	CbGpPWpGaD
Nedocromil—HSP90AA1—Developmental Biology—STAT3—ovarian cancer	0.000135	0.00031	CbGpPWpGaD
Nedocromil—HSP90AA1—Developmental Biology—NRAS—ovarian cancer	0.000135	0.000309	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—PIK3CD—ovarian cancer	0.000134	0.000307	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—MMP9—ovarian cancer	0.000134	0.000307	CbGpPWpGaD
Nedocromil—HSP90AA1—Cell Cycle, Mitotic—MAPK3—ovarian cancer	0.000134	0.000306	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—PTEN—ovarian cancer	0.000133	0.000306	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—CCND1—ovarian cancer	0.000133	0.000305	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—PTEN—ovarian cancer	0.000133	0.000305	CbGpPWpGaD
Nedocromil—CYSLTR2—GPCR downstream signaling—PIK3CA—ovarian cancer	0.000133	0.000304	CbGpPWpGaD
Nedocromil—HSP90AA1—Axon guidance—IL6—ovarian cancer	0.000132	0.000303	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—CTNNB1—ovarian cancer	0.000132	0.000303	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—CXCL8—ovarian cancer	0.000132	0.000302	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling by GPCR—KRAS—ovarian cancer	0.000131	0.000301	CbGpPWpGaD
Nedocromil—FPR1—Signaling by GPCR—AKT1—ovarian cancer	0.00013	0.000298	CbGpPWpGaD
Nedocromil—HSP90AA1—Cell Cycle, Mitotic—MYC—ovarian cancer	0.00013	0.000298	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—MMP9—ovarian cancer	0.000129	0.000297	CbGpPWpGaD
Nedocromil—HSP90AA1—Developmental Biology—MAPK3—ovarian cancer	0.000129	0.000296	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—PTEN—ovarian cancer	0.000129	0.000295	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—TERT—ovarian cancer	0.000129	0.000295	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—TLR4—ovarian cancer	0.000127	0.000292	CbGpPWpGaD
Nedocromil—HSP90AA1—Cell Cycle, Mitotic—MAPK1—ovarian cancer	0.000127	0.000291	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—IL2—ovarian cancer	0.000126	0.000289	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—ABCB1—ovarian cancer	0.000126	0.000288	CbGpPWpGaD
Nedocromil—PTGDR—Signaling by GPCR—AKT1—ovarian cancer	0.000126	0.000288	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—TERT—ovarian cancer	0.000125	0.000287	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—TYMS—ovarian cancer	0.000124	0.000283	CbGpPWpGaD
Nedocromil—HSP90AA1—Developmental Biology—MAPK1—ovarian cancer	0.000123	0.000281	CbGpPWpGaD
Nedocromil—HSP90AA1—Developmental Biology—EGFR—ovarian cancer	0.000123	0.000281	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—IL6ST—ovarian cancer	0.000122	0.00028	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling by GPCR—PIK3CA—ovarian cancer	0.000121	0.000276	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—VEGFA—ovarian cancer	0.00012	0.000276	CbGpPWpGaD
Nedocromil—HSP90AA1—Cell Cycle—MAPK3—ovarian cancer	0.000119	0.000274	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—STAT3—ovarian cancer	0.000119	0.000273	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—NRAS—ovarian cancer	0.000119	0.000273	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—CAV1—ovarian cancer	0.000119	0.000273	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—NRAS—ovarian cancer	0.000119	0.000272	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—ERBB2—ovarian cancer	0.000118	0.000271	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—MTOR—ovarian cancer	0.000117	0.000268	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—PIK3CB—ovarian cancer	0.000117	0.000268	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—VEGFA—ovarian cancer	0.000116	0.000266	CbGpPWpGaD
Nedocromil—HSP90AA1—Cell Cycle—MYC—ovarian cancer	0.000116	0.000266	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—CAV1—ovarian cancer	0.000116	0.000266	CbGpPWpGaD
Nedocromil—HSP90AA1—Developmental Biology—KRAS—ovarian cancer	0.000116	0.000266	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—STAT3—ovarian cancer	0.000115	0.000264	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—NRAS—ovarian cancer	0.000115	0.000263	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—MAPK3—ovarian cancer	0.000114	0.000261	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—MAPK3—ovarian cancer	0.000114	0.000261	CbGpPWpGaD
Nedocromil—HSP90AA1—Cell Cycle—MAPK1—ovarian cancer	0.000114	0.000261	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—PPP2R1A—ovarian cancer	0.000113	0.00026	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—IL6ST—ovarian cancer	0.000113	0.000258	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—CXCL8—ovarian cancer	0.000112	0.000257	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—ESR1—ovarian cancer	0.000112	0.000256	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling by GPCR—HRAS—ovarian cancer	0.000112	0.000256	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—MYC—ovarian cancer	0.000111	0.000254	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—IL6ST—ovarian cancer	0.00011	0.000252	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—MAPK3—ovarian cancer	0.00011	0.000252	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—CDKN1B—ovarian cancer	0.00011	0.000251	CbGpPWpGaD
Nedocromil—CYSLTR2—GPCR downstream signaling—AKT1—ovarian cancer	0.000108	0.000249	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—MAPK1—ovarian cancer	0.000108	0.000249	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—EGFR—ovarian cancer	0.000108	0.000248	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—APC—ovarian cancer	0.000108	0.000248	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—MAPK1—ovarian cancer	0.000108	0.000248	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—EGFR—ovarian cancer	0.000108	0.000248	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—CDH1—ovarian cancer	0.000108	0.000247	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—CASP3—ovarian cancer	0.000107	0.000246	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—IL2—ovarian cancer	0.000107	0.000246	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—MYC—ovarian cancer	0.000107	0.000245	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling by GPCR—IL6—ovarian cancer	0.000107	0.000245	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—APC—ovarian cancer	0.000106	0.000242	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—PIK3CG—ovarian cancer	0.000106	0.000242	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—NRAS—ovarian cancer	0.000106	0.000242	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—CCND1—ovarian cancer	0.000105	0.00024	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—MAPK1—ovarian cancer	0.000105	0.00024	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—EGFR—ovarian cancer	0.000105	0.00024	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—CTNNB1—ovarian cancer	0.000104	0.000237	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—PIK3CD—ovarian cancer	0.000103	0.000236	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—KRAS—ovarian cancer	0.000102	0.000235	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—KRAS—ovarian cancer	0.000102	0.000234	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—MMP9—ovarian cancer	0.000102	0.000233	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—MAPK3—ovarian cancer	0.000101	0.000232	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—PTEN—ovarian cancer	0.000101	0.000231	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—CAV1—ovarian cancer	9.96e-05	0.000228	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—KRAS—ovarian cancer	9.88e-05	0.000226	CbGpPWpGaD
Nedocromil—HSP90AA1—Developmental Biology—HRAS—ovarian cancer	9.86e-05	0.000226	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling by GPCR—AKT1—ovarian cancer	9.85e-05	0.000226	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—MAPK1—ovarian cancer	9.63e-05	0.000221	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—EGFR—ovarian cancer	9.63e-05	0.000221	CbGpPWpGaD
Nedocromil—HSP90AA1—Cell Cycle—TP53—ovarian cancer	9.54e-05	0.000219	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—PIK3CD—ovarian cancer	9.52e-05	0.000218	CbGpPWpGaD
Nedocromil—HSP90AA1—Developmental Biology—IL6—ovarian cancer	9.44e-05	0.000216	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—PIK3CA—ovarian cancer	9.41e-05	0.000216	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—PIK3CA—ovarian cancer	9.4e-05	0.000215	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—PIK3CD—ovarian cancer	9.29e-05	0.000213	CbGpPWpGaD
Nedocromil—CYSLTR1—GPCR downstream signaling—PIK3CA—ovarian cancer	9.2e-05	0.000211	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—VEGFA—ovarian cancer	9.12e-05	0.000209	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—ERBB2—ovarian cancer	9.11e-05	0.000209	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—KRAS—ovarian cancer	9.1e-05	0.000208	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—TP53—ovarian cancer	9.09e-05	0.000208	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—PIK3CA—ovarian cancer	9.08e-05	0.000208	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—PIK3CG—ovarian cancer	9.07e-05	0.000208	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—STAT3—ovarian cancer	9.03e-05	0.000207	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—NRAS—ovarian cancer	9.01e-05	0.000206	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—TERT—ovarian cancer	9e-05	0.000206	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—MTOR—ovarian cancer	8.99e-05	0.000206	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—PIK3CB—ovarian cancer	8.99e-05	0.000206	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—TP53—ovarian cancer	8.78e-05	0.000201	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—HRAS—ovarian cancer	8.71e-05	0.0002	CbGpPWpGaD
Nedocromil—HSP90AA1—Developmental Biology—AKT1—ovarian cancer	8.7e-05	0.000199	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—HRAS—ovarian cancer	8.7e-05	0.000199	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—MAPK3—ovarian cancer	8.63e-05	0.000198	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—CDKN1B—ovarian cancer	8.44e-05	0.000193	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—ERBB2—ovarian cancer	8.41e-05	0.000193	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—HRAS—ovarian cancer	8.4e-05	0.000192	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—MYC—ovarian cancer	8.39e-05	0.000192	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—PIK3CA—ovarian cancer	8.36e-05	0.000192	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—IL6—ovarian cancer	8.33e-05	0.000191	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—CAV1—ovarian cancer	8.33e-05	0.000191	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—IL6—ovarian cancer	8.32e-05	0.000191	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—MTOR—ovarian cancer	8.3e-05	0.00019	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—PIK3CB—ovarian cancer	8.3e-05	0.00019	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—IL2—ovarian cancer	8.26e-05	0.000189	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—MAPK1—ovarian cancer	8.21e-05	0.000188	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—ERBB2—ovarian cancer	8.21e-05	0.000188	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—EGFR—ovarian cancer	8.21e-05	0.000188	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—PIK3CB—ovarian cancer	8.1e-05	0.000186	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—MTOR—ovarian cancer	8.1e-05	0.000186	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—IL6—ovarian cancer	8.04e-05	0.000184	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—ESR1—ovarian cancer	8.03e-05	0.000184	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—PIK3CD—ovarian cancer	7.98e-05	0.000183	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—CTNNB1—ovarian cancer	7.97e-05	0.000183	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—IL6ST—ovarian cancer	7.9e-05	0.000181	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—CDKN1B—ovarian cancer	7.79e-05	0.000179	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—CXCL8—ovarian cancer	7.78e-05	0.000178	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—PTEN—ovarian cancer	7.77e-05	0.000178	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—KRAS—ovarian cancer	7.75e-05	0.000178	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—HRAS—ovarian cancer	7.73e-05	0.000177	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—AKT1—ovarian cancer	7.69e-05	0.000176	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—AKT1—ovarian cancer	7.68e-05	0.000176	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—CDKN1B—ovarian cancer	7.6e-05	0.000174	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—PIK3CG—ovarian cancer	7.59e-05	0.000174	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—APC—ovarian cancer	7.59e-05	0.000174	CbGpPWpGaD
Nedocromil—CYSLTR1—GPCR downstream signaling—AKT1—ovarian cancer	7.52e-05	0.000172	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—CASP3—ovarian cancer	7.45e-05	0.000171	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—IL2—ovarian cancer	7.44e-05	0.00017	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—AKT1—ovarian cancer	7.42e-05	0.00017	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—IL6—ovarian cancer	7.4e-05	0.00017	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—CTNNB1—ovarian cancer	7.36e-05	0.000169	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—CCND1—ovarian cancer	7.25e-05	0.000166	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—CTNNB1—ovarian cancer	7.18e-05	0.000165	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—PTEN—ovarian cancer	7.17e-05	0.000164	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—PIK3CA—ovarian cancer	7.12e-05	0.000163	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—MMP9—ovarian cancer	7.04e-05	0.000161	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—PTEN—ovarian cancer	7e-05	0.00016	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—PIK3CB—ovarian cancer	6.95e-05	0.000159	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—STAT3—ovarian cancer	6.95e-05	0.000159	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—NRAS—ovarian cancer	6.93e-05	0.000159	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—TP53—ovarian cancer	6.89e-05	0.000158	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—AKT1—ovarian cancer	6.83e-05	0.000156	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—PIK3CD—ovarian cancer	6.67e-05	0.000153	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—MAPK3—ovarian cancer	6.64e-05	0.000152	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—HRAS—ovarian cancer	6.59e-05	0.000151	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—STAT3—ovarian cancer	6.42e-05	0.000147	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—NRAS—ovarian cancer	6.4e-05	0.000147	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—VEGFA—ovarian cancer	6.32e-05	0.000145	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—MAPK1—ovarian cancer	6.32e-05	0.000145	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—EGFR—ovarian cancer	6.32e-05	0.000145	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—IL6—ovarian cancer	6.31e-05	0.000145	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—STAT3—ovarian cancer	6.26e-05	0.000143	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—NRAS—ovarian cancer	6.24e-05	0.000143	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—MAPK3—ovarian cancer	6.13e-05	0.00014	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—PTEN—ovarian cancer	6.01e-05	0.000138	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—MAPK3—ovarian cancer	5.98e-05	0.000137	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—KRAS—ovarian cancer	5.97e-05	0.000137	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—MYC—ovarian cancer	5.96e-05	0.000137	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—ERBB2—ovarian cancer	5.89e-05	0.000135	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—MAPK1—ovarian cancer	5.83e-05	0.000134	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—EGFR—ovarian cancer	5.83e-05	0.000134	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—AKT1—ovarian cancer	5.82e-05	0.000133	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—MYC—ovarian cancer	5.82e-05	0.000133	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—MTOR—ovarian cancer	5.81e-05	0.000133	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—PIK3CB—ovarian cancer	5.81e-05	0.000133	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—MAPK1—ovarian cancer	5.69e-05	0.00013	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—EGFR—ovarian cancer	5.69e-05	0.00013	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—CXCL8—ovarian cancer	5.59e-05	0.000128	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—KRAS—ovarian cancer	5.51e-05	0.000126	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—PIK3CA—ovarian cancer	5.48e-05	0.000126	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—CDKN1B—ovarian cancer	5.46e-05	0.000125	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—KRAS—ovarian cancer	5.37e-05	0.000123	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—CASP3—ovarian cancer	5.35e-05	0.000123	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—IL2—ovarian cancer	5.34e-05	0.000122	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—CCND1—ovarian cancer	5.2e-05	0.000119	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—CTNNB1—ovarian cancer	5.15e-05	0.000118	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—HRAS—ovarian cancer	5.07e-05	0.000116	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—PIK3CA—ovarian cancer	5.06e-05	0.000116	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—MMP9—ovarian cancer	5.05e-05	0.000116	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—PTEN—ovarian cancer	5.02e-05	0.000115	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—PIK3CA—ovarian cancer	4.94e-05	0.000113	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—IL6—ovarian cancer	4.85e-05	0.000111	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—TP53—ovarian cancer	4.78e-05	0.000109	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—HRAS—ovarian cancer	4.68e-05	0.000107	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—HRAS—ovarian cancer	4.57e-05	0.000105	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—VEGFA—ovarian cancer	4.54e-05	0.000104	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—STAT3—ovarian cancer	4.49e-05	0.000103	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—NRAS—ovarian cancer	4.48e-05	0.000103	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—IL6—ovarian cancer	4.48e-05	0.000103	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—AKT1—ovarian cancer	4.48e-05	0.000103	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—IL6—ovarian cancer	4.37e-05	0.0001	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—MAPK3—ovarian cancer	4.29e-05	9.84e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—PIK3CA—ovarian cancer	4.24e-05	9.71e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—MYC—ovarian cancer	4.17e-05	9.57e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—AKT1—ovarian cancer	4.13e-05	9.47e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—MAPK1—ovarian cancer	4.08e-05	9.36e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—EGFR—ovarian cancer	4.08e-05	9.36e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—AKT1—ovarian cancer	4.03e-05	9.24e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—KRAS—ovarian cancer	3.86e-05	8.84e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—PIK3CA—ovarian cancer	3.54e-05	8.12e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—AKT1—ovarian cancer	3.46e-05	7.93e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—TP53—ovarian cancer	3.43e-05	7.86e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—HRAS—ovarian cancer	3.28e-05	7.51e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—IL6—ovarian cancer	3.14e-05	7.19e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—AKT1—ovarian cancer	2.89e-05	6.63e-05	CbGpPWpGaD
